中国综合性科技类核心期刊(北大核心)

中国科学引文数据库来源期刊(CSCD)

美国《化学文摘》(CA)收录

美国《数学评论》(MR)收录

俄罗斯《文摘杂志》收录

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

REGγp53,NOTCH1BRAF在甲状腺癌中的表达及其临床意义

亓龙 左娣 王辉 李晓涛

亓龙, 左娣, 王辉, 李晓涛. REGγ,p53,NOTCH1和BRAF在甲状腺癌中的表达及其临床意义[J]. 华东师范大学学报(自然科学版), 2012, (6): 89-95.
引用本文: 亓龙, 左娣, 王辉, 李晓涛. REGγp53,NOTCH1BRAF在甲状腺癌中的表达及其临床意义[J]. 华东师范大学学报(自然科学版), 2012, (6): 89-95.
QI Long, ZUO Di, WANG Hui, LI Xiao-tao. Expressions of REGγ, p53, NOTCH1 and BRAF gene in thyroid cancer and their clinical relevance[J]. Journal of East China Normal University (Natural Sciences), 2012, (6): 89-95.
Citation: QI Long, ZUO Di, WANG Hui, LI Xiao-tao. Expressions of REGγ, p53, NOTCH1 and BRAF gene in thyroid cancer and their clinical relevance[J]. Journal of East China Normal University (Natural Sciences), 2012, (6): 89-95.

REGγp53,NOTCH1BRAF在甲状腺癌中的表达及其临床意义

详细信息
  • 中图分类号: R736.1

Expressions of REGγ, p53, NOTCH1 and BRAF gene in thyroid cancer and their clinical relevance

  • 摘要: 旨在探讨〖WTBX〗REG,p〖STBX〗53,NOTCH1〖STBZ〗〖WTBZ〗和〖WTBX〗BRAF〖WTBZ〗在乳头状甲状腺癌中的表达及其与临床病理因素的相关性.应用Realtime-PCR及免疫组织化学方法检测〖WTBX〗REG,p〖STBX〗53,NOTCH1〖STBZ〗〖WTBZ〗和〖WTBX〗BRAF〖WTBZ〗在乳头状甲状腺癌组织中的表达,分析〖WTBX〗REG〖WTBZ〗与〖WTBX〗〖STBX〗p53,NOTCH1〖STBZ〗,BRAF〖WTBZ〗之间的关系及其与临床病理因素的相关性.〖WTBX〗REG〖WTBZ〗在乳头状甲状腺癌组织中表达明显增高,且其阳性率为87.5%(35/40).〖WTBX〗REG〖WTBZ〗表达与患者年龄、淋巴结转移情况有关(〖WTBX〗P〖WTBZ〗=0.015 10.05),与患者性别无显著性相关(〖WTBX〗P〖WTBZ〗=0.7420.05);〖WTBX〗REG〖WTBZ〗表达与〖WTBX〗〖STBX〗p53,NOTCH1〖STBZ〗〖WTBZ〗和〖WTBX〗BRAF〖WTBZ〗表达呈正相关(〖WTBX〗P〖WTBZ〗=0.023 30.05).〖WTBX〗REG〖WTBZ〗阳性表达可作为乳头状甲状腺癌发生、发展的生物学指标,联合〖WTBX〗〖STBX〗p53〖WTBZ〗、〖WTBX〗〖STBX〗NOTCH1〖STBZ〗〖WTBZ〗和〖WTBX〗BRAF〖WTBZ〗检测可以为临床诊治及预后判断提供参考.
  • [1] [1] OKAMURA T,TANIGUCHI S,OHKURA T,et al.Abnormally high expression of proteasome activator-gamma in thyroid neoplasm[J]. J Clin Endocrinol Metab, 2003, 88(3): 1374-1383.

    [2] RODERICK M,HELEN G,PAOLO G, et al. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and 〖STBX〗p53〖STBZ〗 mutations[J]. CANCER, 2005, 103(11): 2261-2268.

    [3] KIMURA E T, NIKIFOROVA M N, ZHU Z, et al. High prevalence of 〖WTBX〗BRAF〖WTBZ〗 mutations in thyroid cancer genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma[J]. CANCER RESEARCH, 2003, 63: 1454-1457.

    [4] PRATHIBHA R, WEAVER K L, CAPOBIANCO A J. Notch signalling in solid tumours: a little bit of everything but not all the time[J]. Nature, 2011(11): 338-351.

    [5] NIKIFOROVA M N, KIMURA E T, GANDHI M, et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas[J]. J Clin Endocrinol Metab, 2003, 88(11): 5399-5540.

    [6] 沈铭昌.免疫组化在病理学中的应用进展与评价[J].实用肿瘤杂志, 2002, 17(5): 293-294.

    [7] MAO I, LIU J, LI X, et al. REGgamma, a proteasome activator and beyond[J]. Cell Mol Life Sci, 2008, 65(24): 3971-80.

    [8] NIKAIDO T, SHIMADA K, SHIBATA M, et al. Cloning and nucleotide sequence of cDNA for Ki antigen, a highly conserved nuclear protein detected with sera from patients with systemic lupus erythematosus[J]. Clin Exp Immunol, 1990, 79(2): 209-214.

    [9] ROESSLER M, ROLLINGER W, MANTOVANI-ENDL L,et,al. Identification of PSME3 as a novel serum tumor marker for colorectal cancer by combining two-dimensional polyacrylamide gel electrophoresis with a strictly mass spectrometry-based approach for data analysis[J]. Mol Cell Proteomics, 2006, 5(11): 2092-2101.

    [10] OKAMURA T, TANIGUCHI S, OHKURA T,et al. Abnormally high expression of proteasome activator-gamma in thyroid neoplasm[J]. J Clin Endocrinol Metab, 2003, 88(3): 1374-1383.

    [11] SALVATORE G, NAPPI TC, SALERNO P, et al. A cell proliferation and chromosomal instability signature in anaplastic thyroid carcinoma[J]. Cancer Res, 2007, 67(21): 10148-10158.

    [12] DAVIDOFFf A M, HEMDON J E, GLOVER N S, et al. Relation between 〖STBX〗p53〖STBZ〗 overexpression and established prognostic factors in breast cancer[J]. Surgery, 1991, 110(2): 259-264.

    [13] ZHANG Z, ZHANG R.Proteasome activator PA28 gamma regulates 〖STBX〗p53〖STBZ〗 by enhancing its MDM2-mediated degradation[J]. EMBO J, 2008, 27(6): 852-64.

    [14] PEYSSONNAUX C,EYCHENE A. The RAF/MEK/ERKpathway: new concepts of activation[J]. Biol Cell, 2001, 93: 53-62.

    [15] DUESBERY N S,WEBB C P,VANDE W G F.MEK wars,a new front in the battle against cancer[J]. Nat Med, 1999(5): 736-742.

    [16] PARR C,WATKINS G, JIANG W G. The possible correlation of Notch-1 and Notch-2 with clinical outcome and tumer clinicopathological parameters in human breast cancer[J]. Int J Med, 2004, 14(5): 779-786.

    [17] QI R, AN H, YU Y, et al. 〖STBX〗NOTCH1〖STBZ〗 signaling inhibits growth of human hepatocellular crcinoma through induction of cell cycle arrest and apoptosis[J]. Cancer Res, 2003, 63: 8323-8329.
  • 加载中
计量
  • 文章访问数:  2453
  • HTML全文浏览量:  5
  • PDF下载量:  1785
  • 被引次数: 0
出版历程
  • 收稿日期:  2012-01-01
  • 修回日期:  2012-04-01
  • 刊出日期:  2012-11-25

目录

    /

    返回文章
    返回